Overview

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

Status:
RECRUITING
Trial end date:
2027-02-28
Target enrollment:
Participant gender:
Summary
In this study, the investigators provide a combined treatment of personalized tumor neoantigen-based peptide vaccine, PD-1 Inhibitor, and radiotherapy to patients with advanced non-small cell lung cancer (NSCLC) progressed after first-line treatment. The investigators observe the objective response rate (ORR), disease control rate (DCR), adverse event (AE), serious adverse event (SAE), progression-free survival (PFS), and overall survival (OS) , aiming to evaluate the effectiveness and safety of the treatment.
Phase:
NA
Details
Lead Sponsor:
The First Affiliated Hospital of Nanchang University
Treatments:
Immune Checkpoint Inhibitors
Radiotherapy